Αρχική World News Childhood cancer survivors at greater risk of ill health

Childhood cancer survivors at greater risk of ill health

An empty hospital hallway

People who survive cancer in childhood have a higher risk of ill health as they grow older, according to new research published in The Lancet Regional Health – Europe.

The risks vary according to the cancer type and how the cancer was treated. But overall, the study found that people who survived cancer had 5 times as many GP or hospital visits relating to cardiovascular disease by the age of 45, compared to those who never had cancer.

They also had much higher numbers of healthcare visits relating to infections, disorders of the immune system, and subsequent cancers.

The researchers are calling for these long-term health effects to be considered when young people and their families initially discuss treatment options with their healthcare team.

“Over 80% of children and young people diagnosed with cancer survive, but they face unique healthcare needs because of late effects brought on by cancer or its treatment,” said Dr Alvina Lai, senior author of the study.

Professor Marc Mansour, a clinician scientist based at University College London who specialises in blood cancers in children and young people and wasn’t involved in the research, said that this is “an important study because it’s one of the most comprehensive assessments of the long term consequences of cancer treatments performed to date.”

The impact of intense treatment

The researchers compared the anonymous health records of 3,466 people diagnosed with cancer in England before the age of 25, who survived for at least 5 years, with a control group of 13,517 who did not have cancer early in life.

They compared the total number of times people had visited their GP or hospital for a range of 183 physical and mental conditions. The team also analysed based on the type of cancer the survivors originally had, the cancer treatment they received and the dosage of the treatment.

Our study is the first to fully map out how surviving cancer early in life affects our health as we grow older.

Dr Alvina Lai, UCL Institute of Health Informatics

The study found that late health effects were highest for people treated with both chemotherapy and radiotherapy, and lowest for cancer survivors who only had surgery.

People treated with chemotherapy and radiotherapy had more than twice the number of hospital admissions overall by the age of 45 than those who just had surgery.

These patients also had 7 times the number of GP or hospital visits relating to cardiovascular disease by the same age – an average of 7 healthcare encounters per person, compared to 1 per person.

The study found that this group also had an increased risk of getting cancer for the second time, as well as developing more aggressive cancer.

“With more children than ever surviving cancer, this study should help alert patients and health professionals to the late effects of chemo-radiotherapy,” said Mansour.

The researchers also found that those living in the most deprived areas had the highest number of late health effects, highlighting the need for targeted policies aimed at promoting awareness among high-risk individuals.

Mental illness was also a common late effect, suggesting that coordinated physical and psychological care is required.

A need for consideration and awareness

“We believe it’s important for these long-term effects to be considered early on by families and their healthcare teams, so the benefits of a therapy can be weighed against any long-term risk,” said Lai.

“Awareness of these long-term issues is also important for survivors, who are better able to spot symptoms early.”

Mansour notes that awareness means that more vigilant monitoring and being conscious of lifestyle choices could help mitigate some of the long-term side effects of treatment until treatments are able to change.

The long-term effects suffered by childhood cancer survivors can have a major impact not just on quality of life and more hospital visits, but on overall life expectancy as well.

The study calculated that cancer survivors who developed cardiovascular conditions lost an average of 10 years of life compared to survivors who did not.

Those with diseases of the immune system and infections lost an average of 6.7 years. And the development of a subsequent cancer was linked to 11 years of life lost.

“We hope that further research can investigate how to minimise the long-term effects of cancer therapies,” said Lai.

Mansour commented that there is now a major focus on reducing treatment toxicity without sacrificing effectiveness, particularly for more curable cancers like childhood leukaemia.

“Giving lower doses of chemotherapy, avoiding radiotherapy if possible and moving towards more specific targeted therapies that do not cause long term damage to normal tissues are all likely to reduce long term complications.”

More on this topic


Προηγούμενο άρθροThe incredible value of going public
Επόμενο άρθροHandmade Artisan Gifts For Under $30


Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling of Breast Implants

In 2013, Kristen Carbone, of Providence, Rhode Island, had a preventative mastectomy to help protect herself against breast cancer after her mother died of...

FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

On 30 November 2021, the US Food and Drug Administration (FDA) approved daratumumab plus hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen,...

Thanks For Making This GivingTuesday Our Best One Yet!

We set ambitious goals for GivingTuesday, but they were driven by a time of great need. With your help, we hoped to provide food and...

Over 600 people in England set to benefit from innovative lung cancer treatment

<img width="620" height="348" src="https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero.jpg" class="attachment-featuredImage size-featuredImage" alt="Lung cancer cell" loading="lazy" srcset="https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero.jpg 620w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-300x168.jpg 300w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-220x123.jpg 220w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-150x84.jpg 150w" sizes="(max-width: 620px) 100vw, 620px" data-attachment-id="18781" data-permalink="https://news.cancerresearchuk.org/2020/09/11/targeted-drug-for-lung-cancer-approved-for-nhs-use-in-england/lung_cell_cropped-hero/"...

Touching a nerve: How neuroscience could advance our understanding of cancer

KTSDESIGN/SCIENCE PHOTO LIBRARY When supporters donate to our work, their combined generosity might lead to a new discovery that inches us closer to, for example,...

Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients with CUP

An investigator-initiated phase II study is the first to show that nivolumab has clinical activity with manageable toxicity in a statistically evaluable number of...